610 completed. 610 Phase 2, 143 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 610 | Completed 610 |
| Phase 1 | 143 | Completed 143 |
| Phase 3 | 7 | Completed 7 |
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1 - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Hutchmed | 61 | 2024-11-05 | 2026-09-24 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) DZD8586 - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 59 | 2024-03-13 | 2026-08-04 |
| Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab Vedotin, Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Peng Liu | 30 | 2023-12-20 | 2026-10-14 |
| Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL Blinatumomab - B Acute Lymphoblastic Leukemia | Phase 2 | Completed | Chen Suning | 35 | 2022-09-08 | 2024-09-19 |
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab Ociperlimab, Tislelizumab, Rituximab - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 53 | 2022-04-25 | 2025-09-15 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Completed | University of Washington | 42 | 2022-03-23 | 2026-05-13 |
| Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma Selinexor, Flu, CTX - Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-02-10 | 2026-06-02 |
| IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (RCHOP or an investigator's choice) plus IT thiotepa and dexamethasone - Diffuse Large B-Cell Lymphoma (DLBCL), Intrathecal Chemotherapy | Phase 2 | Completed | Zhejiang Cancer Hospital | 31 | 2022-02-01 | 2026-03-25 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) Zilovertamab vedotin - Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 140 | 2022-01-08 | 2026-05-28 |
| Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy Anakinra, X-Ray Imaging, Positron Emission Tomography - B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 27 | 2021-12-27 | 2025-10-23 |
| Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA) - Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos | Phase 2 | Completed | Centre Hospitalier Universitaire, Amiens | 1 | 2021-11-09 | 2026-06-12 |
| Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Capivasertib - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 2 | Completed | AstraZeneca | 30 | 2021-11-03 | 2024-12-20 |
| HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 HST-NEETs, Bone Marrow Transplant - HIV Associated Lymphoma | Phase 2 | Completed | Catherine Bollard | 12 | 2021-10-25 | 2026-06-29 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib Zanubrutinib - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeiGene | 65 | 2021-08-11 | 2026-03-25 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) LOXO-305 - Leukemia, Lymphoid, Lymphoma, Non-Hodgkin | Phase 2 | Completed | Eli Lilly and Company | 87 | 2021-05-14 | 2026-02-06 |
| Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma HMPL-689 - Marginal Zone Lymphoma, Follicular Lymphoma | Phase 2 | Completed | Hutchison Medipharma Limited | 178 | 2021-04-15 | 2025-04-06 |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality AndroGel - Hypogonadism | Phase 2 | Completed | Lars Møller Pedersen | 7 | 2021-04-01 | 2022-11-29 |
| Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL CAR-T cells targeting CD19 and CD22 - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 2 | Completed | Zhejiang University | 28 | 2021-03-05 | 2024-10-17 |
Showing 20 of 610. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (394) · Lymphoma (271) · Lymphoma, Follicular (262) · Lymphoma, Non-Hodgkin (238) · Lymphoma, B-Cell, Marginal Zone (226) · Lymphoma, Mantle-Cell (218) · Burkitt Lymphoma (213) · Leukemia, Lymphocytic, Chronic, B-Cell (210) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (165) · Lymphoma, Large-Cell, Immunoblastic (154) · Hodgkin Disease (127) · Leukemia (114) · Waldenstrom Macroglobulinemia (105) · Recurrence (91)
Hemic and Lymphatic Diseases (610) · Immune System Diseases (607) · Neoplasms by Histologic Type (607) · Immunoproliferative Disorders (604) · Lymphatic Diseases (603) · Lymphoproliferative Disorders (598) · Neoplasms (593) · Lymphoma, Non-Hodgkin (372) · Lymphoma (339) · Hematologic Diseases (292) · Pathologic Processes (260) · Pathological Conditions, Signs and Symptoms (260) · Leukemia, Lymphoid (258) · Disease Attributes (257)
Rituximab (190) · Cyclophosphamide (166) · Etoposide (90) · Vincristine (78) · Doxorubicin (66) · Peripheral Blood Stem Cell Transplantation (66) · Prednisone (65) · Filgrastim (63) · Cytarabine (51) · fludarabine phosphate (50) · Radiotherapy (47) · Methotrexate (41) · Mycophenolic Acid (40) · Busulfan (34) · Whole-Body Irradiation (34)
National Cancer Institute (NCI) (44) · Fred Hutchinson Cancer Center (43) · M.D. Anderson Cancer Center (26) · Memorial Sloan Kettering Cancer Center (26) · Case Comprehensive Cancer Center (13) · Alliance for Clinical Trials in Oncology (12) · Mayo Clinic (12) · Lymphoma Study Association (10) · University of Nebraska (10) · Roswell Park Cancer Institute (9) · BeiGene (8) · City of Hope Medical Center (8) · Masonic Cancer Center, University of Minnesota (8) · Northwestern University (8) · Novartis Pharmaceuticals (8)
United States (447) · France (62) · Italy (52) · United Kingdom (43) · Germany (39) · Spain (33) · Canada (32) · China (28) · Belgium (26) · South Korea (22) · Australia (21) · Switzerland (21) · Austria (19) · Poland (18) · Netherlands (16)
Ajay Gopal (6) · Brenda Sandmaier (6) · Craig Moskowitz, MD (6) · Julie M Vose, MD (5) · Lode J. Swinnen, MD (5) · Sonali Smith (5) · Thomas E. Witzig, MD (5) · David Maloney (4) · Leo I. Gordon, MD (4)
PMID 34515338, PMID 32499241, PMID 26373676, PMID 27282998, PMID 30125215, PMID 17242396, PMID 21527516, PMID 23834234, PMID 24224624, PMID 24862638, PMID 27209293, PMID 29437592, PMID 31196847, PMID 32209572, PMID 33496754, PMID 34310745, PMID 34353848, PMID 34398557, PMID 34432863, PMID 34780125, PMID 35422096, PMID 35622074, PMID 38775302, PMID 39240498, PMID 10673703, PMID 11600602, PMID 12907446, PMID 1403051, PMID 14508361, PMID 14630682, PMID 14739217, PMID 14767498, PMID 15042678, PMID 15386331, PMID 15613697, PMID 15779863, PMID 16731764, PMID 16966261, PMID 17312330, PMID 17515574, PMID 17610262, PMID 17910637, PMID 17943599, PMID 18079362, PMID 18245545, PMID 18270560, PMID 18327587, PMID 18413640, PMID 18569634, PMID 18612102
P30CA015704 (16), P30CA043703 (10), U10CA032102 (9), 2015 (8), U10CA031946 (8), 2014 (7), P30CA006973 (7), P30CA015083 (7), P30CA033572 (7), P30CA036727 (7), P01CA018029 (6), 2016 (5), 2017 (4), N01CM62201 (4), N01CM62202 (4)